Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 21;8(10):e012239.
doi: 10.1161/JAHA.119.012239.

Current Landscape of Heart Failure Gene Therapy

Jake M Kieserman  1 , Valerie D Myers  1 , Praveen Dubey  1 , Joseph Y Cheung  1 , Arthur M Feldman  1
Affiliations
Review

Current Landscape of Heart Failure Gene Therapy

Jake M Kieserman et al. J Am Heart Assoc. .
No abstract available

Keywords: dilated cardiomyopathy; gene therapy; genetics; heart failure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Current heart failure gene therapy approaches targeted to cardiac excitation‐contraction coupling. With depolarization, extracellular Ca2+ enters by L‐type Ca2+ channels (IC a), triggering Ca2+ release from the ryanodine receptor (RyR2) in the sarcoplasmic reticulum (SR). Ca2+ in the sarcoplasm binds to troponin to initiate contraction. During diastole, Ca2+ is resequestered in the SR by SR Ca2+‐ATPase (SERCA2a), whose activity is regulated by phospholamban (PLB). The amount of Ca2+ that has entered during systole is largely extruded by Na+/Ca2+ exchanger (NCX1; utilizing the electrochemical gradient established by Na+‐K+‐ATPase NaK) and, to a much smaller extent, the sarcolemmal Ca2+‐ATPase (not shown). When β‐adrenergic receptor (βAR) is stimulated, cAMP is generated, which activates protein kinase A (PKA), which, in turn, increases IC a and RyR2 activities and Ca2+ sensitivity of myofilaments, thereby enhancing contractility. PKA also phosphorylates PLB, thereby relieving its inhibition on SERCA2a, resulting in enhanced SR Ca2+ uptake, which improves both contraction (larger SR Ca2+ content leading to larger intracellular Ca2+ transients) and relaxation (faster SR Ca2+ sequestration during diastole). Current gene therapy products (shown in rectangular red boxes) target βAR (AC6, βARKct), SR Ca2+ uptake (SERCA2a), PLB (I‐1c), and Ca2+ cycling by RyR2 and SERCA2a (S100A1). BAG3 has multiple downstream effectors, including IC a, myofilaments, and mitochondria; not shown are autophagy, nuclear envelope integrity, and cell‐to‐cell communication (connexin43), also positively regulated by BAG3. Urocortins effect mainly vasodilation and are not shown here. SERCA2a indicates sarcoplasmic/endoplasmic reticulum calcium ATPase 2a.
See this image and copyright information in PMC

References

    1. Nabel EG, Plautz G, Nabel GJ. Site‐specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990;249:1285–1288. - PubMed
    1. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996;348:370–374. - PubMed
    1. Yla‐Herttuala S, Baker AH. Cardiovascular gene therapy: past, present, and future. Mol Ther. 2017;25:1095–1106. - PMC - PubMed
    1. Petrus I, Chuah M, VandenDriessche T. Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med. 2010;12:797–809. - PubMed
    1. Mattila M, Koskenvuo J, Soderstrom M, Eerola K, Savontaus M. Intramyocardial injection of SERCA2a‐expressing lentivirus improves myocardial function in doxorubicin‐induced heart failure. J Gene Med. 2016;18:124–133. - PubMed

Publication types